The Rheumatic Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Rheumatic Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rheumatic Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rheumatic Disorders and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Rheumatic Disorders by six companies/universities/institutes. The top development phase for Rheumatic Disorders is preclinical with four drugs in that stage. The Rheumatic Disorders pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Rheumatic Disorders pipeline products market are: Promomed Rus, Mabscale and Mozart Therapeutics.
The key targets in the Rheumatic Disorders pipeline products market include Receptor Type Tyrosine Protein Kinase FLT3, Tumor Necrosis Factor, and T Cell Surface Glycoprotein CD8 Alpha Chain.
The key mechanisms of action in the Rheumatic Disorders pipeline product include Tumor Necrosis Factor Inhibitor with one drug in Phase I. The Rheumatic Disorders pipeline products include three routes of administration with the top ROA being Subcutaneous and two key molecule types in the Rheumatic Disorders pipeline products market including Monoclonal Antibody, and Cell Therapy.
Rheumatic Disorders overview
Rheumatic disorders are the group of diseases which affects joints, tendons, ligaments, bones, and muscles. Among them are many types of arthritis, a term used for conditions that affect your joints. Sometimes they’re called musculoskeletal diseases.
For a complete picture of Rheumatic Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
